HomeCompareCBAY vs BTI

CBAY vs BTI: Dividend Comparison 2026

CBAY yields 6.16% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BTI wins by $7.7K in total portfolio value· pulled ahead in Year 2
10 years
CBAY
CBAY
● Live price
6.16%
Share price
$32.48
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.0K
Annual income
$911.52
Full CBAY calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — CBAY vs BTI

📍 BTI pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCBAYBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CBAY + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CBAY pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CBAY
Annual income on $10K today (after 15% tax)
$523.40/yr
After 10yr DRIP, annual income (after tax)
$774.79/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, BTI beats the other by $1,593.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CBAY + BTI for your $10,000?

CBAY: 50%BTI: 50%
100% BTI50/50100% CBAY
Portfolio after 10yr
$33.9K
Annual income
$1,849.08/yr
Blended yield
5.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CBAY right now

CBAY
Analyst Ratings
11
Buy
12
Hold
Consensus: Hold
Altman Z
12.9
Piotroski
4/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CBAY buys
0
BTI buys
0
No recent congressional trades found for CBAY or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCBAYBTI
Forward yield6.16%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$30.0K$37.7K
Annual income after 10y$911.52$2,786.64
Total dividends collected$7.7K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy

Year-by-year: CBAY vs BTI ($10,000, DRIP)

YearCBAY PortfolioCBAY Income/yrBTI PortfolioBTI Income/yrGap
1$11,316$615.76$11,299$598.92+$17.00CBAY
2← crossover$12,759$651.20$12,794$703.91$35.00BTI
3$14,338$686.22$14,518$829.07$180.00BTI
4$16,063$720.72$16,513$978.64$450.00BTI
5$17,942$754.57$18,827$1,157.84$885.00BTI
6$19,985$787.70$21,518$1,373.12$1.5KBTI
7$22,204$820.02$24,657$1,632.46$2.5KBTI
8$24,610$851.47$28,329$1,945.74$3.7KBTI
9$27,215$881.98$32,637$2,325.33$5.4KBTI
10$30,031$911.52$37,708$2,786.64$7.7KBTI

CBAY vs BTI: Complete Analysis 2026

CBAYStock

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Full CBAY Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this CBAY vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CBAY vs SCHDCBAY vs JEPICBAY vs OCBAY vs KOCBAY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.